Interchangeable Biosimilar Approval: FDA Greenl...

By João L. Carapinha

November 17, 2025

FDA Grants First Interchangeable Biosimilar Approval for HER2-Positive Breast Cancer Treatment The U.S. Food and Drug Administration (FDA...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Biosimilars Market Trends 2025: Understanding Erosion and Growth
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflamma...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Econ...